Nabi-HB Webpages Omit Risk Information, FDA Warning Letter States
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Biologics Evaluation & Research says omitted risk information "is necessary to qualify the effectiveness claims appearing" on webpages for the hepatitis agent. FDA requests that Nabi distribute non-misleading and complete information to the audiences that viewed the violative materials.